Pharmaceutical giant AstraZeneca announced Monday that their investigational drug tozorakimab successfully achieved a “meaningful reduction” in serious flare-ups among patients with chronic obstructive pulmonary disease during a major clinical trial, adding to encouraging results from previous studies.
The medication successfully achieved its primary objective in the “MIRANDA” clinical study, providing a “statistically significant and clinically meaningful” decrease in yearly rates of moderate-to-severe COPD episodes among both active smokers and those who had quit smoking.
During the trial, participants who kept experiencing moderate-to-severe episodes while on standard inhaled treatments received either 300 mg doses of tozorakimab or an inactive placebo administered every two weeks alongside their regular therapy.
These latest findings strengthen investor confidence in the treatment’s potential following tozorakimab’s success in achieving primary endpoints in two additional late-stage studies conducted in March, where it similarly demonstrated effectiveness in reducing COPD flare-ups.
